European Journal of Heart Failure

Article	Citations
Simultaneous or rapid sequence initiation of medical therapies for heart failure: seeking to avoid the case of ‘too little, too late’	1371
November 2021 at a glance: focus on prevention, comorbidities, cardiogenic shock and novel devices	239
Are left ventricular ejection fraction phenotypes meaningful in acute heart failure?	210
Striving for the ‘perfect’ definition of iron deficiency in heart failure	165
Reply to ‘Morphine use in acute cardiogenic pulmonary oedema: is MIMO trial enough to change practice?’	149
Issue Information	134
Letter regarding the article ‘Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure’	134
Improving renal function during diuresis: useful information or just noise?	131
	124
Corrigendum to ‘Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy’ [Eur J Heart Fail	120
Identifying reliable biomarkers for pulmonary congestion: Toward a close yet sustainable heart failure follow‐up	116
Salt repletion and diuretic response: The role of serum chloride. A post‐hoc analysis of the SALT‐HF trial on furosemide and hypertonic saline solution administration in ambulato	112
Effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum in PARAGON‐HF	112
Association of preoperative infections, nasal Staphylococcus aureus colonization and gut microbiota with left ventricular assist device outcomes	105
Heart failure: age is no excuse for complacency	103
Applying the ‘touch‐and‐go’ concept to mineralocorticoid receptor antagonists: A paradigm shift in routine heart failure management	103
Dissecting the heart failure phenotype through phenomics	96
Issue Information	94
Reply to the letter regarding the article ‘Are mechanical circulatory supports the forgotten aspect in the implementation of therapies for heart failure?’	93
Time‐varying analyses of survival and outcomes in patients with HeartMate 3 left ventricular assist devices	92
Incidence and predictors of weaning failure from veno‐arterial extracorporeal membrane oxygenation therapy in patients with cardiogenic shock	91
Adrenomedullin as a marker of hypoxia, not hypoperfusion. Letter regarding the article ‘Biologically active adrenomedullin as a marker for residual congestion and early rehospitalization in patients h	88
Left ventricular volume and maximal functional capacity in heart failure with preserved ejection fraction: Size matters	87
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial	87
Burst steroid therapy for acute heart failure: The CORTAHF randomized, open‐label, pilot trial	87

Cardiovascular magnetic resonance‐estimated pulmonary capillary wedge pressure, congestion markers, and effect of empagliflozin in patients with heart failure with reduced ejection fraction	85
Exercise catheterization in adults post‐Fontan with normal and abnormal haemodynamic criteria: Insights into normal Fontan physiology	84
Abstract	83
Culture, ethnicity, and socio‐economic status as determinants of the management of patients with advanced heart failure who need palliative care: A clinical consensus statement from the Heart Failure	78
Tafamidis in patients with severe heart failure due to transthyretin amyloidosis cardiomyopathy: Improved long‐term survival	72
Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant‐level pooled analysis from the DAPA‐HF and DELIVER trials	67
Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial	64
Rationale and design of the ESC Heart Failure III Registry – Implementation and discovery	63
Percutaneous repair of moderate‐to‐severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE‐HF2 trial	61
Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS‐HF and RALES	60
Similarities and distinctions between acetazolamide and sodium–glucose cotransporter 2 inhibitors in patients with acute heart failure: Key insights into ADVOR and EMPULSE	59
Risk factors for the development of heart failure in patients with or without prior myocardial infarction	59
Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials	58
Issue Information	55
Decongestion strategies in patients presenting with acutely decompensated heart failure: A worldwide survey among physicians	55
Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial	55
Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology	55
Predicting worsening heart failure with preserved ejection fraction from non‐invasive exercise testing	54
July 2023 at a glance: heart failure with preserved ejection fraction and comorbidities	54
Indexing left ventricular end‐systolic dimension to body size: Association with mortality in patients with degenerative mitral regurgitation	54
The dangerous liaison between epicardial adipose tissue and heart failure with preserved ejection fraction	54
Reply to ‘A clinical classification method with outstanding advantages for quickly identifying hazardous types’	54
Cardiopulmonary functional capacity: another piece of the puzzle of sodium–glucose cotransporter 2 inhibition in heart failure?	53
Issue Information	52
Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure	51
Reply to the letter regarding the article ‘Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care’	51
Aortic valve disease and heart failure with mildly reduced ejection fraction: New insights and pending questions	51
December 2021 at a glance: focus on medical treatment, valvular heart disease and prognostic models	51
Use of loop diuretics in chronic heart failure: do we adhere to the Hippocratian principle “do no harm”?	51
Normal and excessive muscle sympathetic nerve activity in heart failure: implications for future trials of therapeutic autonomic modulation	50
The effect of intravenous ferric carboxymaltose on right ventricular function – insights from the IRON‐CRT trial	50
Diagnostic pathways to wild‐type transthyretin amyloid cardiomyopathy: a multicentre network study	49
The different risk of new‐onset, chronic, worsening, and advanced heart failure: A systematic review and meta‐regression analysis	49
Guidance on the management of left ventricular assist device (LVAD) supported patients for the non‐LVAD specialist healthcare provider: executive summary	48
Sex differences in the generalizability of randomized clinical trials in heart failure with reduced ejection fraction	48
Effect of long‐term tafamidis treatment on health‐related quality of life in patients with transthyretin amyloid cardiomyopathy	47
Erythropoietic response after intravenous iron in patients with heart failure and reduced ejection fraction with and without background treatment with sodium–glucose cotransporter 2 inhibitors	47
Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR‐Reduced	47
Long‐term clinical experience with cardiac contractility modulation therapy delivered by the Optimizer Smart system	47
	47
The cost‐effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: A European health‐economic analysis of the DELIVER trial	47
Remote patient management of heart failure across the ejection fraction spectrum: A pre‐specified analysis of the TIM‐HF2 trial	46
Landscape of glycolytic metabolites and their regulating proteins in myocardium from human heart failure with preserved ejection fraction	46
Corrigendum to ‘Congestion in heart failure: A circulating biomarker‐based perspective’ and articles listed below	46
Revascularization in ischaemic heart failure with preserved ejection fraction: a nationwide cohort study	46
Predicting survival in patients with severe heart failure: Risk score validation in the HELP‐HF cohort	45
Cardiac autonomic neuropathy and risk of incident heart failure among adults with type 2 diabetes	45
Letter regarding the article ‘Efficacy and safety of angiotensin receptor–neprilysin inhibition in heart failure patients with end‐stage kidney disease on maintenance dialysis: A systematic review and	45
Serial direct sodium removal in patients with heart failure and diuretic resistance	45
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: A FIDELITY analysis	45

Use of mechanical circulatory support in patients with non‐ischaemic cardiogenic shock	45
404‐error “Disease not found”: Unleashing the translational potential of ‐omics approaches beyond traditional disease classification in heart failure research	45
Low blood pressure and the effect of empagliflozin in acute heart failure: An EMPULSE analysis	44
Cardiogenic shock centres for optimal care coordination and improving outcomes in cardiogenic shock	44
Health status across major subgroups of patients with heart failure and preserved ejection fraction	43
	43
	42
Systemic embolism in transthyretin amyloid cardiomyopathy: how to look into the future	42
	42
Reporting quality of heart failure randomized controlled trials 2000–2020: Temporal trends in adherence to CONSORT criteria	42
Clonal haematopoiesis is associated with major adverse cardiovascular events in patients with hypertrophic cardiomyopathy	42
Reply to ‘Sodium–glucose cotransporter 2 inhibitor treatment lowers serum uric acid in patients with heart failure with reduced ejection fraction – lessons from clinical trials’	42
Post‐discharge arrhythmic risk stratification of patients with acute myocarditis and life‐threatening ventricular tachyarrhythmias	41
Sodium–glucose co‐transporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism	41
Comparison of pulmonary congestion severity using artificial intelligence‐assisted scoring versus clinical experts: A secondary analysis of BLUSHED‐AHF	41
Differential sex‐related effect of left ventricular ejection fraction trajectory on the risk of mortality and heart failure readmission following hospitalization for acute heart failure: A longitudina	41
Delivering more evidence for the specificities of heart failure with improved ejection fraction: New answers, new questions	41
Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo‐controlled multic	40
Biventricular cardiac power reserve in heart failure with preserved ejection fraction	40
Impact of COVID‐19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial	39
Revolutionizing cardiogenic shock treatment: Is the microaxial flow pump the ultimate game changer?	39
Changes in mid‐regional pro‐adrenomedullin during treatment with sacubitril/valsartan	39
Late diagnosis in cancer sparks outrage—so why not heart failure?	39
Managing water and salt balance in heart failure: Is there anything else to consider other than diet and diuretics?	38
Plasma biomarkers associated with adverse outcomes in patients with calcific aortic stenosis	38
Use of guideline‐recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence	38
The utilization and impact of cardiovascular specialists on guideline‐directed medical scores: An analysis of a diverse, multi‐state, electronic health record‐based registry	37
Trends in heart failure mortality in Sweden between 1997 and 2022	37
Cost‐effectiveness of dapagliflozin for patients with heart failure across the spectrum of ejection fraction: A pooled analysis of DAPA‐HF and DELIVER data	37
Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON‐HF	37
Issue Information	36
Sodium–glucose cotransporter 2 inhibition, uric acid, and heart failure: correlation without causation?	36
Corrigendum to “Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction”	36
Disproportionate exercise‐induced pulmonary hypertension in relation to cardiac output in heart failure with preserved ejection fraction: a non‐invasive echocardiographic study	36
Supplement Article	36
Artificial intelligence in heart failure improving the efficiency or dependency on it? Letter regarding the article ‘Artificial intelligence and heart failure: A state‐of‐the‐art review’	36
No longer from pillar to post: The first effective step in treating heart failure with preserved ejection fraction	35
Decreased left ventricular ejection fraction is associated with increased mortality in sepsis: A retrospective cohort study	35
Reply to the letter regarding the article ‘Head‐to‐head comparison between recommendations by the ESC and ACC/AHA/HFSA heart failure guidelines’	35
Comparative effectiveness of sacubitril/valsartan versus angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers in patients with de novo heart failure with mildly reduced and preserved	35
Clinical trials: conventional or pragmatic?	35
Analysing the accuracy of pressure measurements during exercise with pulmonary artery pressure sensors – Insights from the ACTION‐MEMS study	35
More than just a clinical syndrome: Biomarkers and echocardiography should be rapidly advised for anyone with suspected heart failure!	34
Predicting heart failure: The promise of proteomics	34
Heart failure after left atrial appendage occlusion: Insights from the LAAOS III randomized trial	33
Diuretics in pregnancy: Data from the ESC Registry of Pregnancy and Cardiac disease (ROPAC)	33
Withdrawn: Major gaps in the information provided to patients before implantation of cardioverter defibrillators: a prospective patient European evaluation	33
Long‐term survival after acute heart failure hospitalization: from observation to collaborative interventions	32
Trajectories in New York Heart Association functional class in heart failure across the ejection fraction spectrum: data from the Swedish Heart Failure Registry	32
Sympathetic vasoconstrictor activity before and after left ventricular assist device implantation in patients with end‐stage heart failure	32
Effect of patient‐centered transitional care services on patient‐reported outcomes in heart failure: sex‐specific analysis of the PACT‐HF randomized controlled trial	32
Remote pulmonary artery pressure‐guided management of patients with heart failure: A clinical consensus statement of the Heart Failure Association (HFA) of the ESC	32
The heart during iron deficiency: a non‐rechargeable battery?	32
Enrolling patients in cardiogenic shock trials: are we missing someone? Insights from the Italian AltShock‐2 registry	32
The impact of early surgery on mortality in infective endocarditis complicated by heart failure – How much more data do we need?	32
Issue Information	32
Can we prevent infections in patients with left ventricular assist devices?	32
Issue Information	31
Issue Information	31
Transcatheter edge‐to‐edge repair: fix the heart, heal the liver	31
Arrhythmic risk management after acute myocarditis: never too early, only too late	31
Recovery of cardiac function following COVID‐19	31
Plasma soluble fms‐like tyrosine kinase‐1, placental growth factor, and vascular endothelial growth factor system gene variants as predictors of survival in heart failure	31
Issue Information	31
Reply to the letter regarding the article ‘Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure’	31
Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA‐HF and DELIVER	31
Assessing health status after discharge for decompensated heart failure: a patient‐centred priority	31
Cardiac reverse remodelling with vericiguat: Victory or no victory?	31
End‐organ protective effect of serelaxin in patients hospitalized for heart failure: Results of the biomarker substudy of Relaxin in Acute Heart Failure‐2 (RELAX‐AHF‐2)	30
	30
On‐treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post‐hoc analysis of TRANSFORM‐HF	30
The right side of the circulation in not secondary heart failure with preserved ejection fraction: an elephant in the room?	30
Sodium–glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: Treat the heart, cherish the kidney	30
Diabetic myocardial disorder. A clinical consensus statement of the Heart Failure Association of the ESC and the ESC Working Group on Myocardial & Pericardial Diseases	29
Clinical features, haemodynamics, and outcomes of heart failure with preserved ejection fraction in coarctation of aorta	29
Concomitant latent pulmonary vascular disease leads to impaired global cardiac performance in heart failure with preserved ejection fraction	29
Diuretic efficiency of a single dose of subcutaneous versus oral furosemide after heart failure hospitalization across diuretic resistance strata: A pilot randomized controlled trial	29
Impact of age on clinical outcomes and response to serelaxin in patients with acute heart failure: An analysis from the RELAX‐AHF‐2 trial	29
Evolocumab has no effects on heart failure with reduced ejection fraction injury biomarkers: The EVO‐HF trial	29
Early changes in renal function during rapid up‐titration of guideline‐directed medical therapy following an admission for acute heart failure	29

Association of clonal haematopoiesis with heart failure incidence and outcomes: A systematic review and meta‐analysis	29
The diverging role of epicardial adipose tissue in heart failure with reduced and preserved ejection fraction: not all fat is created equal	29
European Society of Cardiology quality indicators for the care and outcomes of adults with pulmonary arterial hypertension. Developed in collaboration with the Heart Failure Associatio	29
Clinical and plasma proteomic characterization of heart failure with supranormal left ventricular ejection fraction: An emerging entity of heart failure	29
Growth differentiation factor‐15 and the effect of empagliflozin in heart failure: Findings from the EMPEROR program	28
Preventive catheter ablation for ventricular arrhythmias in patients with end‐stage heart failure referred for heart transplantation evaluation: Rationale for and design of the CASTLE‐	28
Cardiac contractility modulation therapy improves health status in patients with heart failure with preserved ejection fraction: a pilot study (CCM‐HFpEF)	28
Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency	28
Midazolam versus morphine in acute cardiogenic pulmonary oedema: results of a multicentre, open‐label, randomized controlled trial	28
Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS‐HF trial	28
Contemporary insights into the epidemiology, impact and treatment of secondary tricuspid regurgitation across the heart failure spectrum	28
Machine learning approach to identify phenotypes in patients with ischaemic heart failure with reduced ejection fraction	28
The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of	28
Measures of left atrial function predict incident heart failure in a low‐risk general population: the Copenhagen City Heart Study	27
Myocardial perfusion in cardiac amyloidosis	27
Effect of allogeneic adipose tissue‐derived mesenchymal stromal cell treatment in chronic ischaemic heart failure with reduced ejection fraction – the SCIENCE trial	27
Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: The VICTORIA echocardiographic substudy	27
Underestimation of congestion in very obese heart failure with preserved ejection fraction patients: EAT your heart out…?!	26
Time to treat the climate and nature crisis as one indivisible global health emergency	26
Reply to the letter regarding the article ‘Acute heart failure after non‐cardiac surgery: incidence, phenotypes, determinants and outcomes’	26
Transthyretin amyloidosis: the picture is getting clearer	26
June 2021 at a glance: focus on epidemiology, biomarkers and medical treatment	26
Clinical outcomes with digoxin vs. beta‐blocker for heart rate control in permanent atrial fibrillation with heart failure	26
When and how? Two simple questions to determine cancer status and inform therapeutic decisions and trial design in heart failure	26
Circulating levels of procollagen type I carboxy‐terminal propeptide reflect myocardial fibrosis	26
Reply to ‘Epicardial adipose tissue: does it mediate the cardio‐protective effects of sodium–glucose co‐transporter 2 inhibitors in subjects with heart failure?’ Letter regarding the article ‘Impact o	26
Prioritizing prevention of de novo and worsening chronic heart failure	26
Worsening heart failure comes into focus, chronic heart failure takes a backseat	26
Improve heart function to improve heart failure outcomes: the disease‐modifying effects of spironolactone	25
Corrigendum to ‘Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials’ [Eur J Heart Fail 2016;18:684–692]	25
Corrigendum to ‘Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction’ [Eur J Heart Fail 2021; 23: 983–991]	25
	25
When is the time right? Dancing on the tightrope: referral for upgrade to cardiac resynchronization therapy	25
Right heart failure as a cause of pulmonary congestion in pulmonary arterial hypertension	25
Skeletal muscle and subcutaneous fat quantity as prognostic indicators in cardiac amyloidosis	25
Letter regarding the article ‘Heart failure with improved versus persistently reduced left ventricular ejection fraction: A comparison of the BIOSTAT‐CHF (European) study with th	25
Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trial	25
Growth differentiation factor‐15: A promising biomarker for early detection of pre‐heart failure	25
Bug attack! The rising importance of Chagas disease	25
Implementing the evidence – the true summit of evidence‐based care and the false peak of guidelines	24
Efficacy of the COVID‐19 vaccine in heart transplant recipients: what we know and what we ignore	24
A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the	24
Iron deficiency testing and treatment in heart failure: the eyes are useless when the mind is blind	24
If a patient does not require treatment with loop diuretics, do they really have heart failure?	24
Early and short‐term intensive management after discharge for patients hospitalized with acute heart failure: a randomized study (ECAD‐HF)	24
Early changes in estimated glomerular filtration rate post‐initiation of empagliflozin in EMPEROR‐Reduced	24
Is it NICE to measure natriuretic peptides after a hospitalization for heart failure?	24
The role of kidney disease progression in heart failure prognosis: Bridging the evidence gap for optimal management	24
Peri‐procedural management of transcatheter mitral valve replacement in patients with heart failure	24
Pulmonary vascular disease in heart failure with preserved ejection fraction: the evidence grows	24
Feasibility and efficacy of transcatheter interatrial shunt devices for chronic heart failure: a systematic review and meta‐analysis	23
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study	23
Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm A	23
Artificial intelligence methods for improved detection of undiagnosed heart failure with preserved ejection fraction	23
Tricuspid regurgitation: Frequency, clinical presentation, management and outcome among patients with severe left‐sided valvular heart disease in Europe. Insights from the ESC‐EORP Valvular	23
Heart failure treatment in the last years of life: A nationwide study of 364 000 individuals	23
Guideline‐directed medical therapy for heart failure in arrhythmia‐induced cardiomyopathy with improved left ventricular ejection fraction	22
Characteristics and outcomes of patients with atrial versus ventricular secondary tricuspid regurgitation undergoing tricuspid transcatheter edge‐to‐edge repair – Results from the TriValve	22
Splanchnic nerve block with botulinum toxin for therapy of chronic heart failure – mechanism of action (SPONGE‐HF)	22
Natriuretic peptides, body mass index and heart failure risk: Pooled analyses of SAVOR‐TIMI 53, DECLARE‐TIMI 58 and CAMELLIA‐TIMI 61	22
Safety and performance of a novel implantable sensor in the inferior vena cava under acute and chronic intravascular volume modulation	22
Device‐based remote monitoring strategies for congestion‐guided management of patients with heart failure: a systematic review and meta‐analysis	22
Reply to the letter regarding the article ‘Association of clonal haematopoiesis with heart failure incidence and outcomes: A systematic review and meta‐analysis’	22
Risk and risk reduction in trials of heart failure with reduced ejection fraction: absolute or relative?	22
Time to reconsider the perception and management of hypertensive heart disease	22
Neuropeptide Y is elevated in heart failure and is an independent predictor of outcomes	22
Reply to: ‘What is the optimal dose of neurohormonal modulators in patients with heart failure? The higher the better?’	21
Epicardial adipose tissue: does it mediate the cardio‐protective effects of sodium–glucose co‐transporter 2 inhibitors in patients with heart failure? Letter regarding the article ‘Impact of epicardia	21
The splanchnic reservoir: an oasis for blood volume in heart failure with preserved ejection fraction?	21
Functional mitral regurgitation: a proportionate or disproportionate focus of attention?	21
Intentional weight loss in overweight and obese patients with heart failure: A systematic review	21
	21
A Heart Team approach to contemporary device decision‐making in heart failure	20
Supplement Article	20
Heart failure related central sympathetic activation: debunking the ‘holy grail’?	20
Kidney involvement in transthyretin cardiac amyloidosis – Role of urinary albumin to creatinine ratio and need for further evidence generation	20
New cardiovascular biomarkers in patients with advanced cancer – A prospective study comparing MR‐proADM, MR‐proANP, copeptin, high‐sensitivity troponin T a	20
The pharmacist ally in heart failure: Useful when involved. Letter regarding the article ‘Effective medications can work only in patients who take them: Implications for post‐acute heart failure care’	20
Persistent high mortality in acute myocardial infarction‐associated cardiogenic shock despite early mechanical circulatory support: Need for stepwise and integrated approach of care	20
Issue Information	20
	20
A machine‐learning‐based prediction model in patients with takotsubo syndrome: ‘You can't stop change any more than you can stop the suns from setting!’	20
Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: The VICTOR trial	20
Predicting survival after Impella implantation in patients with cardiogenic shock: The J‐PVAD risk score	19
Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: Rationale and design of the HF‐REVERT trial	19
Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients	19
Additional burden of iron deficiency in heart failure patients beyond the cardio‐renal anaemia syndrome: findings from the BIOSTAT‐CHF study	19
Giant cell myocarditis after first dose of BNT162b2 – a case report	19
Iron deficiency and supplementation in patients with heart failure: Results from the IRON‐HF international survey	19
Iron deficiency in heart failure: screening, prevalence, incidence and outcome data from the Swedish Heart Failure Registry and the Stockholm CREAtinine Measurements collaborativ	19
Residual tricuspid regurgitation after tricuspid transcatheter edge‐to‐edge repair: Insights into the EuroTR registry	19
Defining changes in physical limitation from the patient perspective: insights from the VITALITY‐HFpEF randomized trial	19
In‐hospital course of patients with heart failure with improved ejection fraction in the DELIVER trial	19
Head‐to‐head comparison between recommendations by the ESC and ACC/AHA/HFSA heart failure guidelines	19
College‐level reading is required to understand ChatGPT's answers to lay questions relating to heart failure	19